US EditionBrii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
- On May 7, 2025, Brii Biosciences presented end-of-treatment results from Cohort 4 of the ENSURE Phase 2 clinical trial during the EASL Congress held in Amsterdam.
- The study builds on prior findings that BRII-179, a recombinant protein vaccine, can differentiate immune responders and improve hepatitis B surface antigen clearance when combined with elebsiran and PEG-IFN.
- In Cohort 4, which consisted of 28 participants previously treated with BRII-179, HBsAg seroclearance was observed in 61% of those who developed an anti-HBs response, whereas only 10% of participants without such a response reached seroclearance by Week 48, indicating quicker and greater levels of antigen clearance in responders.
- David Margolis, Chief Medical Officer, explained that BRII-179 treatment helps recognize individuals with relatively stronger natural immune function and enhances their immune activity, which could lead to more sustained HBsAg clearance and allow for shorter courses of PEG-IFN therapy.
- These results suggest BRII-179 enhances functional cure outcomes in chronic HBV infection and support further investigation of elebsiran and PEG-IFN combinations to meet high unmet medical needs globally, especially in China.
54 Articles
54 Articles
The Berkshire Eagle
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 naïve participants, strengthening the case…
End-of-treatment (EOT) data from ENSURE cohort 4 demonstrate that patients who responded to prior BRII-179 treatment achieved faster and higher surface antigen clearance rates after curative therapy compared to BRII-179-naïve patients, highlighting a novel enrichment strategy to identify and immune-activate patients with BRII-179 to improve functional cure outcomes 24-week follow-up results from ENSURE cohorts 1-3 demonstrate sustained non-thera…
Coverage Details
Bias Distribution
- 59% of the sources are Center
To view factuality data please Upgrade to Premium